<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This analysis compares the safety and tolerability of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (a thiazolidinedione), <z:chebi fb="0" ids="6801">metformin</z:chebi> (a <z:chebi fb="0" ids="3095">biguanide</z:chebi>), and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> (a <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Data collected from four 1-year, double-blind studies comparing treatment of over 3700 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, or <z:chebi fb="0" ids="31654">gliclazide</z:chebi> have been combined to provide comparative tolerability and safety profiles </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatments were well tolerated with approximately 6% of patients withdrawing from treatment because of side-effects </plain></SENT>
<SENT sid="3" pm="."><plain>The side-effects profile varied between treatments, with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> being associated with <z:hpo ids='HP_0000969'>edema</z:hpo>, <z:chebi fb="0" ids="6801">metformin</z:chebi> with gastrointestinal side-effects, and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> with <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Cardiovascular outcome was similar with <z:hpo ids='HP_0000001'>all</z:hpo> treatments, with no excess reports of <z:hpo ids='HP_0001635'>cardiac failure</z:hpo> with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Both <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> resulted in mean <z:mp ids='MP_0005456'>weight gain</z:mp>, whilst with <z:chebi fb="0" ids="6801">metformin</z:chebi> there was mean <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Mean liver enzyme values decreased with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and to a lesser extent with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>With <z:chebi fb="0" ids="31654">gliclazide</z:chebi>, mean liver enzyme values increased </plain></SENT>
<SENT sid="8" pm="."><plain>The expected small decreases in mean <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and hematocrit seen with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> also occurred with <z:chebi fb="0" ids="6801">metformin</z:chebi> and to a lesser degree with <z:chebi fb="0" ids="31654">gliclazide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>The results show that <z:hpo ids='HP_0000001'>all</z:hpo> three drugs are safe, but that tolerability profiles vary </plain></SENT>
<SENT sid="10" pm="."><plain>Each treatment provides an alternative therapy for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, dependent on the particular needs of individual patients </plain></SENT>
</text></document>